HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy.
Saved in:
| Title: | HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy. |
|---|---|
| Authors: | Nozawa K; Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.; Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Sawaki M; Department of Breast Oncology, Nagoya Medical Center, Nagoya, Japan., Uemura Y; Biostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health and Medicine, Shinjuku, Japan., Tsuneizumi M; Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan., Takano T; Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Koto, Japan., Gondo N; Department of Breast and Thyroid Surgical Oncology, Sagara Hospital, Kagoshima, Japan., Hara F; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Harao M; Department of Breast Oncology, Jichi Medical University, Shimotsuke, Japan., Toyama T; Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Taira N; Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan., Vivancos A; Reveal Genomics, Barcelona, Spain., Perou CM; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Sanfeliu E; Reveal Genomics, Barcelona, Spain., Brasó-Maristany F; Reveal Genomics, Barcelona, Spain., Parker JS; Reveal Genomics, Barcelona, Spain., Buckingham W; Reveal Genomics, Barcelona, Spain., Paré L; Reveal Genomics, Barcelona, Spain., Villacampa G; Statistics Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Marín-Aguilera M; Reveal Genomics, Barcelona, Spain., Villagrasa P; Reveal Genomics, Barcelona, Spain., Prat A; Reveal Genomics, Barcelona, Spain. alprat@clinic.cat.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. alprat@clinic.cat.; Department of Medical Oncology, Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain. alprat@clinic.cat.; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain. alprat@clinic.cat.; Department of Medicine, University of Barcelona, Barcelona, Spain. alprat@clinic.cat., Iwata H; Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. |
| Source: | Nature communications [Nat Commun] 2025 Nov 04; Vol. 16 (1), pp. 9585. Date of Electronic Publication: 2025 Nov 04. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-65599-x |
